Takeda to return molecules/ products for Japan to Amgen

pharmafile | June 27, 2016 | News story | Manufacturing and Production, Research and Development, Sales and Marketing |  Amgen, Cancer, Japan, Takeda Pharmaceutical, drug development, drug trial 

Japanese firm Takeda Pharmaceutical (TSE: 4502) said it will return the rights to develop and market multiple molecules/ products from Amgen’s (Nasdaq: AMGN) pipeline for the Japanese market.

Under the revised agreement the company will return rights for the molecules AMG403 and AMG386, effective immediately, the company said in a statement.

Takeda and Amgen will continue to collaborate on remaining molecules/ products for the Japanese market, including Vectibix (panitumumab), a leading treatment for unresectable advanced or recurrent colorectal cancer, Takeda said.

Phil Rowlands, interim head, oncology therapeutic area unit, Takeda, said: “Through our work with Amgen, we have successfully delivered Vectibix to the Japanese patients facing a challenging diagnosis while continuing to build our scientific understanding of novel treatment pathways. We look forward to continuing our scientific discovery and to building a portfolio of innovative medicines through our ongoing collaboration with Amgen.”

No financial details were disclosed.

Anjali Shukla